Cancer research in focus: ESMO 2025 impresses with innovations in Berlin!

Cancer research in focus: ESMO 2025 impresses with innovations in Berlin!

Last week, Berlin experienced a significant moment in cancer research: The 50th Anniversary Congress of the European Society for Medical Oncology (ESMO) was a meeting place for oncology experts from all over the world. The exchange of new scientific findings and advances in drug development was the focus of the event, which is considered the most important interdisciplinary cancer congress in Europe.

Lots of exciting information was shared and Johnson & Johnson stood out among the exhibitors.The company presented the latest study results in oncology in 16 presentations and two satellite symposiums. Contact points included the treatment of EGFR-mutant lung cancer and new target structures in head and neck cancer.

‘); ?>

Focus on innovative therapies

Cancer patients can be happy: Urs Voegeli, CEO of Janssen-Cilag GmbH, emphasized that progress in the treatment of solid tumors is progressing. The central topics also included the potential for metastatic castration-resistant prostate cancer and research into bladder-preserving approaches for bladder cancer. Johnson & Johnson's goal remains clear: a world without cancer and improving the quality of life of patients.

Combination of techniques

Another exciting point of the congress was the exchange about new developments in targeted cancer therapy. In addition to research into antibody-drug conjugates (ADCs) for HER2+ metastatic breast cancer, aspects of artificial intelligence in drug development were also discussed. The role of AI in predicting survival outcomes was a key theme.

The first findings on new combination strategies that were tested in several studies in heavily pretreated patients with ovarian and prostate cancer were particularly impressive. The effectiveness of novel CAR-T cells against myeloma was also presented.

Myelofibrosis: A silent companion

When discussing various cancers, the term myelofibrosis was also mentioned. This form of bone marrow cancer is often characterized by scarring in the bone marrow. The clinical picture is sometimes limited to minor symptoms, but in other cases it can lead to serious symptoms.The challenge is that many sufferers do not require immediate treatment, while others suffer from severe symptoms.

Symptoms include fatigue, pain, excessive sweating and heart palpitations. It is indeed important to seek medical attention promptly if you experience any noticeable symptoms, as even the mildest forms of myelofibrosis can cause serious problems if left untreated.

Overall, the ESMO Congress 2025 provided an important platform to advance the latest scientific advances in the fight against cancer. The exchange of knowledge and collaboration between the medical community are crucial steps towards better cancer care.